• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20010 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Vasopressin as first-line therapy for cardiac arrest: a review of the guidelines and clinical-effectiveness
2015     Health Quality Ontario (HQO) Vasodilators for inhospital heart failure management: a rapid review (update)
2013     Health Quality Ontario (HQO) Vasodilators for inhospital heart failure management: a rapid review
2020     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Vascular-targeted photodynamic therapy with padeliporfin (Tookad® Soluble)
1989     The Swedish Council on Health Technology Assessment (SBU) Vascular surgery for arteriosclerosis in the legs
2007     Institute for Clinical Effectiveness and Health Policy (IECS) Vascular endothelial growth factor inhibitors (pegaptanib, ranibizumab and bevacizumab) in age-related macular degeneration treatment
2007     Institute for Clinical Effectiveness and Health Policy (IECS) Vascular endothelial growth factor inhibitors (pegaptanib, ranibizumab and bevacizumab) in age-related macular degeneration treatment
2004     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Vascular bipolar electrocoagulation (LigaSure (TM)) and Tissular electrocoagulation and section (TissueLink (TM)) - preliminary report
2000     University HealthSystem Consortium (UHC) Varicella-zoster
2014     New Zealand National Health Committee (NHC) Varicella and rotovirus vaccination in New Zealand - assessment reports
2020     NIHR Health Services and Delivery Research programme Variations in the organisation of Early Pregnancy Assessment Units (EPAUs) in the UK and their effects on clinical, service and patient-centred outcomes (VESPA)
1993     Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS) Variations in the frequency of surgical procedures by region in the province of Quebec - nonsystematic review
1996     Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS) Variations in rates of tonsillectomy, adenoidectomy and myringotomy in Quebec - nonsystematic review
2014     NIHR Health Services and Delivery Research programme Variations in outcome and costs among NHS providers for common surgical procedures: econometric analyses of routinely collected data
2017     NIHR Health Services and Delivery Research programme Variations in mortality across the week following emergency admission to hospital: linked retrospective observational analyses of hospital episode data in England, 2004/5 to 2013/14
2014     NIHR Health Services and Delivery Research programme Variation in compulsory psychiatric inpatient admission in England: a cross-sectional, multilevel analysis
2001     Health Council of the Netherlands Gezondheidsraad (GR) Variant Creutzfeldt-Jakob disease and blood transfusion - review, expert panel
2009     NIHR Health Technology Assessment programme Varenicline in the management of smoking cessation: a single technology appraisal
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Varenicline for smoking cessation in patients with psychiatric illness: a review of the risks
2007     National Institute for Health and Clinical Excellence (NICE) Varenicline for smoking cessation
2009     Center for Evidence-based Practice (CEP) Varenicline for smoking cessation
2007     Quality Improvement Scotland (NHS QIS ) Varenicline for smoking cessation
2007     NIHR Horizon Scanning Centre (NIHR HSC) Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer
2007     NIHR Horizon Scanning Centre (NIHR HSC) Vandetanib (Zactima, -6474, AZD-6474, ZD6474) for medullary thyroid cancer – locally advanced or metastatic
2015     NIHR Horizon Scanning Centre (NIHR HSC) Vandetanib (Caprelsa) for locally advanced or metastatic differentiated thyroid cancer – second line
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Vancomycin-resistant enterococci isolation and screening strategies: clinical evidence and cost-effectiveness
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Vancomycin or metronidazole for treatment of clostridium difficile infection: clinical and economic analyses
2011     Agency for Healthcare Research and Quality (AHRQ) Values of older adults related to primary and secondary prevention
2006     Agency for Healthcare Research and Quality (AHRQ) Value of the periodic health evaluation
2007     Haute Autorite de sante (HAS) Value of mutation detection and of the activated protein C resistance assay in inherited thrombophilia
2005     Haute Autorite de sante (HAS) Value of measuring FSH and LH levels in women aged 45 or over
2007     Haute Autorite de sante (HAS) Value of mandibular advancement devices in cases of obstructive sleep apnea-syndrome
1999     Hannover Medical School, Medizinische Hochschule Hannover (MHH) Value of intravascular ultrasound (IVUS) in diagnostic and therapeutic heart catherisation in patients with coronary heart disease - an economic health technology assessment
2007     Haute Autorite de sante (HAS) Value of intensity-modulated radiation therapy
2006     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) Value of intensified nursing
2007     Haute Autorite de sante (HAS) Value of extra-cranial stereotactic radiotherapy
1994     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Value of echoendoscopy in gastrointestinal disease
2014     University of York Value based commissioning of MSK Procedures: an appraisal of the evidence for the proposed policies
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Valsartan (Diovan®)
2020     Institute for Clinical and Economic Review (ICER) Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value
2002     Centre for Clinical Effectiveness (CCE) Validity of the venous thromboembolism risk factor assessment model as described by Motykie et al (2000)
2002     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Validation: dementia in elder people - primary research
2020     NIHR Health Technology Assessment programme Validation and development of models using clinical, biochemical and ultrasound markers for predicting pre-eclampsia: an individual participant data meta-analysis
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Valganciclovir (Valcyte®) tablets
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Valganciclovir (Valcyte®) powder for oral solution
2008     HAYES, Inc. Valerian for treatment of insomnia
2002     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Valdecoxib
2001     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vagus nerve stimulator (VNS)
2022     Agency for Care Effectiveness (ACE) Vagus nerve stimulation with the VITARIA System for heart failure with reduced ejection fraction
1998     Wessex Institute for Health Research and Development (WIHRD) Vagus nerve stimulation in epilepsy
2006     Blue Cross Blue Shield Association (BCBS) Vagus nerve stimulation for treatment-resistant depression
2009     National Institute for Health and Clinical Excellence (NICE) Vagus nerve stimulation for treatment-resistant depression
2005     Blue Cross Blue Shield Association (BCBS) Vagus nerve stimulation for treatment-resistant depression
1998     ECRI Vagus nerve stimulation for the treatment of intractable epilepsy
2004     National Institute for Clinical Excellence (NICE) Vagus nerve stimulation for refractory epilepsy in children
1998     Alberta Heritage Foundation for Medical Research (AHFMR) Vagus nerve stimulation for refractory epilepsy
2001     Alberta Heritage Foundation for Medical Research (AHFMR) Vagus nerve stimulation for refractory epilepsy
2006     Institute for Clinical Effectiveness and Health Policy (IECS) Vagus Nerve Stimulation for refractory epilepsy
2001     Alberta Heritage Foundation for Medical Research (AHFMR) Vagus nerve stimulation for refractory epilepsy
2008     Adelaide Health Technology Assessment (AHTA) Vagus nerve stimulation for epilepsy
2009     HAYES, Inc. Vagus nerve stimulation for epilepsy
2008     Medical Services Advisory Committee (MSAC) Vagus nerve stimulation for epilepsy
2003     HAYES, Inc. Vagus nerve stimulation for epilepsy
2007     HAYES, Inc. Vagus nerve stimulation for epilepsy
2014     HAYES, Inc. Vagus nerve stimulation for epilepsy
2009     HAYES, Inc. Vagus nerve stimulation for depression
2005     HAYES, Inc. Vagus nerve stimulation for depression
2013     HAYES, Inc. Vagus nerve stimulation for depression
2009     HAYES, Inc. Vagus nerve stimulation for depression
2001     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vagus nerve stimulation (VNS) for treatment-resistant depression
2000     Alberta Heritage Foundation for Medical Research (AHFMR) Vagus nerve stimulation
1997     Alberta Heritage Foundation for Medical Research (AHFMR) Vaginoplasty in male-female transsexuals and criteria for sex reassignment surgery
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Vaginal preparation prior to cesarean delivery: clinical evidence
2021     Ontario Health Vaginal pessaries for pelvic organ prolapse and stress urinary incontinence
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Vaginal micronized progesterone capsules for the prevention of miscarriage and preterm birth: a review of the clinical evidence
2000     HAYES, Inc. Vaginal hormonal cytology for the diagnosis and management of menopause
2010     Adelaide Health Technology Assessment (AHTA) Vaginal brachytherapy for treatment of women with high-intermediate risk of endometrial cancer
1993     Danish Institute for Health Services Research (DSI) Vaginal bleeding disorders. Consensus statement
2010     Agency for Healthcare Research and Quality (AHRQ) Vaginal birth after cesarean: new insights
2003     Agency for Healthcare Research and Quality (AHRQ) Vaginal birth after Cesarean (VBAC)
2005     Technology Assessment Unit of the McGill University Health Centre (MUHC) Vacuum-assisted wound closure therapy (V.A.C (R))
2000     ECRI Vacuum-assisted wound closure for chronic and acute wounds
2003     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vacuum-assisted closure for the management of wounds: an accelerated systematic review
2006     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) Vacuum-assisted breast biopsy
2003     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vacuum assisted wound closure therapy
2004     Medical Advisory Secretariat (MAS) Vacuum assisted closure therapy for wound care
2003     Quality Improvement Scotland (NHS QIS ) Vacuum assisted closure (VAC) for wound healing
2005     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccines for prevention of human papillomavirus infection
2015     NIHR Health Technology Assessment programme Vaccines for preventing influenza in healthy adults (A060)
2005     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccines for metastatic hormone-refractory prostate cancer
2006     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccines for HIV
2006     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccines for avian influenza
2012     Belgian Health Care Knowledge Centre (KCE) Vaccine safety surveillance in Belgium : place and limits of a background rate approach
2006     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccine for herpes zoster
2006     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccine for herpes simplex
2010     NIHR Health Technology Assessment programme Vaccine effectiveness in pandemic influenza - primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine
2000     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination policies in case of an influenza pandemic
2011     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination of young children against tuberculosis
2013     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination of infants against pneumococcal infections (3)
2003     Health Council of the Netherlands Gezondheidsraad (GR) Vaccination of children against hepatitis B